ECOG E1105: Paclitaxel, Carboplatin, and Trastuzumab plus Bevacizumab or Placebo Versus Paclitaxel and Trastuzumab plus Bevacizumab or Placebo

CTSU S0226: Anastrozole versus Anastrozole and Fulvestrant--Must be post menopausal

CTSU S0550: Circulation Tumor Cell (CTC) levels--used to determined wether the chemotherapy should be modified

GENENTECH TDM4450g: Trastuzumab-MCC-DM1 versus Trastuzumab and Docetaxel

CTSU C40502: Weekly Paclitaxel versus weekly albumin bound nad-paclitaxer or Ixabepilone with Bevacizumab

Pfizer A6181068--Any HER 2 status, any ER / PR--Single agent Sunitinib

ECOG E1104--HER2 +, any ER / PR--Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) + Herceptin with or without chemotherapy--Locally advance recurrence is OK (SUSPENDED 10/07)

CTSUN0733--HER2+, Previously treated with Trastuzumab and anthracycline or taxane--Capecitabine and Lapatinib + / - IMC-A12

GENENTECH TDM4374g: Trastuzumab-MCC-DM1

Post menopausal only & ER positive and / or PR positive

1-2 prior endocrine treatment, may have one prior chemo--CTSU C40302--HER +, ER+ /PR-- Fulvestrant + Lapatinib versus Fulvestrant + Placebo

CTSU C40503: Hormonal therapy + / - Bevacizumab